Meeting
2021 ASCO Annual Meeting
A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.
Authors
Johanna C. Bendell
Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN
Johanna C. Bendell , Alexander I. Spira , Ramez Nassef Eskander , Ezra E.W. Cohen , Geoffrey Kuesters , Christopher Plescia , Karen Campbell , Omid Hamid , Tiffany Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04672980
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2664)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2664
Abstract #
TPS2664
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.
First Author: Frank M. Speetjens
Poster
2020 ASCO Virtual Scientific Program
KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.
First Author: Kedar Kirtane
Poster
2022 ASCO Annual Meeting
A phase 1/2 study of RTX-224, an engineered red blood cell expressing 4-1BB ligand and membrane-bound IL-12, for the treatment of patients with select advanced solid tumors.
First Author: Alexander I. Spira
Poster
2022 ASCO Annual Meeting
A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.
First Author: Scott Norberg